sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
About this trial
This is an observational trial for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating focused on measuring CIDP, MMN, Spinal fluid, CD163, CD19
Eligibility Criteria
Inclusion Criteria:
- Patients diagnosed with CIDP or MMN or patients suspected to have CIDP or MMN
Controls:
- Age >18 years
Exclusion Criteria:
- <18 years
- Acute infections including neuroinfection
- Diabetes
- Other disorders known to have elevated levels of sCD163 and CD19
- Disorders or treatments that contraindicate a lumbar puncture.
Sites / Locations
- Department of Neurology, Aarhus University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
CIDP/MMN newly diagnosed (drug naive)
CIDP/MMN treated
Other peripheral neuropathies
Syptomatic controls
Patients, who are suspected to suffer from CIDP or MMN, will undergo a lumbar puncture as a part of the diagnostic procedure. We expect to include 5-10 patients. Lumbar puncture Blood sample
All patients with established CIDP in maintenance treatment with SCIG or IVIG are recruited from local registries at the outpatient clinic at Department of Neurology, Aarhus University Hospital. We expect that 10-15 patients with CIDP and MMN treated with SCIG or IVIG eligible for inclusion. Furthermore, we expect to include 10 CIDP and MMN patients in maintenance therapy from the outpatient clinics at Department of Neurology, Odense University Hospital and Department of Neurology, Aalborg University Hospital.
Patients who are diagnosed with other causes of peripheral neuropathies than CIDP. We expect to include 20 patients
Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study plus healthy controls. We expected to include 40-50 symptomatic controls